title: Bone metabolism during interferon-alpha treatment of essential thrombocythemia.
abstract: In-vitro studies have demonstrated that interferon (IFN) has an inhibitory effect on bone formation. Changes in bone metabolism were investigated in 19 patients treated for essential thrombocythemia with IFN-alpha. Serum biochemical parameters of bone remodeling [total alkaline phosphatase, osteocalcin, type-I procollagen carboxy-terminal propeptide (PICP), cross-linked telopeptide type-I collagen (ICTP)] and mineral metabolism (total calcium, inorganic phosphate, parathyroid hormone, 25-hydroxyvitamin D) were measured before and after long-term IFN-alpha treatment. The effects of the cumulative IFN-alpha dose and duration of therapy on biochemical markers of bone metabolism were analyzed. No uniform trend or pattern was observed in the measured biochemical parameters except for ICTP, which decreased after treatment. Correlations indicated modulation of bone metabolism, i.e. remodeling with suppression of resorption, as a consequence of therapy with IFN-alpha.
authors.affiliation: Institute of Clinical Chemistry and Department of Medicine, University Hospital Merkur, Zagreb, Croatia.
authors.forename: Rajko
authors.initials: R
authors.lastname: Kusec
authors.forename: Vesna
authors.initials: V
authors.lastname: Kusec
authors.forename: Bettina
authors.initials: B
authors.lastname: Gisslinger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Woloszczuk
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000097:blood; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects*; D016898:Interferon-alpha; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood; D010710:Phosphates / Q000097:blood; D010976:Platelet Count; D011347:Procollagen / Q000097:blood; D011863:Radioimmunoassay; D011994:Recombinant Proteins; D012016:Reference Values; D013223:Statistics as Topic; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D024042:Collagen Type I; D007370:Interferon Type I; D016898:Interferon-alpha; D010446:Peptide Fragments; D010455:Peptides; D010710:Phosphates; D011347:Procollagen; D011994:Recombinant Proteins; C052929:collagen type I trimeric cross-linked peptide; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; D014807:Vitamin D; D003094:Collagen; C104450:25-hydroxyvitamin D; D000469:Alkaline Phosphatase; D002118:Calcium; C554129:interferon alfa-2c